Logo for Unity Biotechnology Inc

Unity Biotechnology Investor Relations Material

Latest events

Logo for Unity Biotechnology Inc

Investor Update

Unity Biotechnology
Logo for Unity Biotechnology

Q4 2023

15 Apr, 2024
Logo for Unity Biotechnology

Corporate Presentation

29 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Unity Biotechnology Inc

Access all reports
Unity Biotechnology, Inc., a biotechnology company, focuses on developing therapeutics designed to slow, halt, or reverse diseases associated with aging. The company's research primarily targets cellular senescence and age-related biology, with an emphasis on ophthalmologic and neurologic diseases. Unity Biotechnology's product pipeline includes UBX1325, currently in clinical trials for treating age-related eye diseases such as diabetic macular edema and age-related macular degeneration. It is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.